Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products

Dongchen An,Steve Peigneur,Louise Antonia Hendrickx,Jan Tytgat

DOI: https://doi.org/10.3390/ijms21145064

IF: 5.6

2020-07-17

International Journal of Molecular Sciences

Abstract:Cannabinoid receptors (CB1 and CB2), as part of the endocannabinoid system, play a critical role in numerous human physiological and pathological conditions. Thus, considerable efforts have been made to develop ligands for CB1 and CB2, resulting in hundreds of phyto- and synthetic cannabinoids which have shown varying affinities relevant for the treatment of various diseases. However, only a few of these ligands are clinically used. Recently, more detailed structural information for cannabinoid receptors was revealed thanks to the powerfulness of cryo-electron microscopy, which now can accelerate structure-based drug discovery. At the same time, novel peptide-type cannabinoids from animal sources have arrived at the scene, with their potential in vivo therapeutic effects in relation to cannabinoid receptors. From a natural products perspective, it is expected that more novel cannabinoids will be discovered and forecasted as promising drug leads from diverse natural sources and species, such as animal venoms which constitute a true pharmacopeia of toxins modulating diverse targets, including voltage- and ligand-gated ion channels, G protein-coupled receptors such as CB1 and CB2, with astonishing affinity and selectivity. Therefore, it is believed that discovering novel cannabinoids starting from studying the biodiversity of the species living on planet earth is an uncharted territory.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The problems that this paper attempts to solve mainly focus on the following aspects:

1. **Clarify the current research status of cannabinoid receptors (CB1 and CB2)**: Firstly, the paper briefly introduces the basic information of CB1 and CB2 receptors, including their structural characteristics, expression patterns and physiological functions in the human body. In particular, it is discussed that CB1 is mainly expressed in the central nervous system, while CB2 is mainly expressed in the immune system, which determines their potential application values in the treatment of different diseases.

2. **Explore new progress in structure - based drug discovery**: With the development of cryo - electron microscopy technology, researchers can understand the structures of CB1 and CB2 receptors in more detail, which is of great significance for structure - based drug design. The paper discusses how this structural information promotes the development of new cannabinoid receptor ligands, especially selective ligands for CB2 receptors, because CB2 receptors may avoid CB1 - receptor - related adverse mental side effects when treating multiple diseases.

3. **Summarize the discovery of new cannabinoids in natural products**: In addition to traditional plant - derived cannabinoids, the paper also introduces new peptide - like cannabinoids from animal sources, such as polypeptides isolated from animal venoms. These polypeptides have the potential as new therapeutic drugs, especially in avoiding the mental side effects of traditional cannabinoids.

4. **Look forward to future research directions**: Finally, the paper discusses the possibility of using animal venoms as an unexplored resource for finding new CB1 and CB2 receptor ligands. Given that the polypeptides contained in animal venoms have high affinity and selectivity for multiple molecular targets, research in this area may bring new drug discovery opportunities.

In conclusion, this paper aims to comprehensively review and analyze the current status of cannabinoid receptor research and explore the potential of using natural products, especially animal venoms, as the development of new therapeutic drugs.